Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

7 results
12:00 AM, May 12, 2014  |  BC Week In Review | Clinical News  |  Clinical Status

Niraparib: Phase III started

from Merck (see BioCentury, June 11, 2012). Under a June 2013 deal, Tesaro will use BRACAnalysis
to respond to niraparib for enrollment in Phase III trials of the product. Myriad markets BRACAnalysis
12:00 AM, Oct 07, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

BMN-673: Phase III ongoing

Myriad Genetics Inc. (NASDAQ:MYGN, Salt Lake City, Utah) said BioMarin will use Myriad's BRACAnalysis in BioMarin's …
a companion diagnostic to stratify patients in the BMN 673 clinical program. Myriad Genetics markets BRACAnalysis
12:00 AM, Sep 09, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

Olaparib: Phase III started

chemotherapy. AstraZeneca is conducting the trial with the Gynecologic Oncology Group. AstraZeneca will use the BRACAnalysis
12:00 AM, Sep 09, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

Olaparib: Phase III started

the trial with the European Network of Gynecological Oncological Trial Groups. AstraZeneca will use the BRACAnalysis
12:00 AM, Jul 29, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

Niraparib: Phase III started

niraparib from Merck (see BioCentury, June 11, 2012). Under a June deal, Tesaro will use BRACAnalysis
or BRCA2 mutations who were previously treated with an anthracycline and a taxane. Myriad markets BRACAnalysis
12:00 AM, Jul 02, 2007  |  BC Week In Review | Clinical News  |  Clinical Status

AZD2281: Phase II started

40 patients with advanced, BRCA1- or BRCA2-positive ovarian cancer. Patients will be identified using the BRACAnalysis
12:00 AM, Jul 02, 2007  |  BC Week In Review | Clinical News  |  Clinical Status

AZD2281: Phase II started

40 patients with advanced, BRCA1- or BRCA2-positive breast cancer. Patients will be identified using the BRACAnalysis